AI Consensus Investment Thesis
LLY: Eli Lilly and Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Eli Lilly and: 1-Year and 5-Year Forecast Outlook and Rating
Eli Lilly and (LLY) has an immediate No Action - Keep Monitoring consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $1,244 for , with -3.09% expected return (-2.77% including net dividends) and a PARTIAL SELL rating.
The 5-year target is $1,630 for , with +26.98% expected return (+29.27% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 1,284, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0.36%. As of 2026-10-20.
Gross TTM: 0.52% · Two-year annualized gross: 0.49%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0.6% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Eli Lilly and Flagship Insight
Metabolic Volume Scaling Converts Surging Demand Into Massive Cash Generation
There is high consensus that surging cardiometabolic prescription volume and oral small-molecule adoption will double operational earnings over five years. However, sharp divergence exists regarding valuation durability, as persistent gross-to-net price erosion and elevated bond yields enforce mechanical multiple compression.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Warren Buffett (Value Purist)
J.P. Morgan (Titan)
Michael Burry (Vulture)
Sherlock Holmes (Whistleblower)
Superintelligence (Anthropologist)
Universal Investor (Polymath)
Ray Dalio (Strategist)
Elon Musk (Visionary)
Machiavelli (Insider)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Eli Lilly and: forecast questions
What is Eli Lilly and (LLY)'s 1-year price forecast?
Eli Lilly and's 1-year target is $1,244 for Sept 2027. The current AI rating is PARTIAL SELL. The expected return from the recorded close is -3.09%, or -2.77% modeled return including net dividends. Latest available market price: USD 1,284, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Eli Lilly and (LLY)'s 5-year price forecast?
Eli Lilly and's 5-year target is $1,630 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +26.98%, or +29.27% modeled return including net dividends. Latest available market price: USD 1,284, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 1,284, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Eli Lilly and forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Eli Lilly and differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Eli Lilly and is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Eli Lilly and: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Eli Lilly and at the latest market close (20 Oct 2026): $12,927 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
* Return is calculated incl. 0.4% net dividend yield for Eli Lilly and.
The base-case investment thesis resolves around a powerful economic tension: unprecedented volumetric expansion across metabolic franchises versus persistent valuation multiple compression. Surging prescription demand for injectable tirzepatide, combined with the primary-care rollout of oral orforglipron, drives revenue from eighty billion dollars toward one hundred thirty billion dollars. Because multi-billion-dollar manufacturing investments have crest commercial validation, operating margins hold above forty-four percent, converting scale into immense free cash flow. Nonetheless, valuation multiples face systemic compression from thirty-nine times toward twenty-four times earnings under five percent benchmark yields and statutory drug price negotiations. Net earnings expansion comfortably outpaces multiple deflation, securing durable total returns.
Key insights
- Oral small-molecule commercialization decouples volume growth from complex injectable cold-chain logistics, unlocking primary-care demographics at structurally superior marginal production costs.
- Cresting manufacturing capital expenditures transition the corporate capital structure from cash absorption into prolific free cash flow generation exceeding thirty billion dollars.
- Statutory Medicare negotiations and pharmacy benefit manager rebate widening enforce double-digit realized price erosion, establishing volume growth as the sole earnings driver.
Eli Lilly and: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 1,284, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0.36%. As of 2026-10-20.
Gross TTM: 0.52% · Two-year annualized gross: 0.49%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 0.6% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 1,153. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $1,177 | +2.08% | -8.31% | -8.26% | Robust third-quarter incretin volumes and early oral channel fill drive solid revenue growth, though elevated Treasury yields constrain multiple expansion. | $1,084 | $1,211 | $750 | |
| $1,214 | +3.15% | -5.43% | -5.29% | Record full-year earnings confirm expanding operating cash flow, but conservative guidance highlights ongoing gross-to-net realized price concessions across commercial books. | $1,116 | $1,259 | $736 | |
| $1,241 | +2.25% | -3.32% | -3.09% | Scaling small-molecule oral manufacturing lowers unit costs and expands margins, counterbalancing the implementation of statutory government price demonstration models. | $1,151 | $1,297 | $743 | |
| $1,244 | +0.23% | -3.09% | -2.77% | Mid-year formulary rebate renegotiations induce temporary gross-to-net margin compression, keeping equity price appreciation subdued despite rising patient script counts. | $1,105 | $1,349 | $755 | |
| $1,278 | +2.74% | -0.44% | -0.02% | Pivotal regulatory submissions for triple-agonist retatrutide and expanded cardiometabolic comorbidity indications re-energize forward earnings visibility and institutional accumulation. | $1,116 | $1,402 | $776 | |
| $1,311 | +2.56% | +2.13% | +2.66% | Full-year results highlight surging free cash conversion as prior manufacturing builds achieve operational validation, funding expanded share repurchases. | $1,160 | $1,459 | $787 | |
| $1,340 | +2.21% | +4.39% | +5.02% | Initial commercial launch preparations for retatrutide offset headline noise from competitor trial readouts, preserving steady underlying operating profit growth. | $1,184 | $1,517 | $803 | |
| $1,349 | +0.71% | +5.09% | +5.83% | Election-year drug pricing rhetoric and Medicare negotiation announcements create sector multiple drag, temporarily masking double-digit international volume gains. | $1,148 | $1,517 | $812 | |
| $1,391 | +3.07% | +8.36% | +9.22% | Broadened commercial reimbursement for obesity-related heart failure and sleep apnea drives high-margin volume, supporting a constructive year-end equity advance. | $1,171 | $1,578 | $839 | |
| $1,415 | +1.75% | +10.23% | +11.20% | Annual financial disclosures demonstrate operating income surpassing fifty billion dollars, with oral formulations capturing substantial primary-care and emerging-market share. | $1,148 | $1,625 | $851 | |
| $1,439 | +1.70% | +12.10% | +13.19% | Challenger entries in oral and dual-agonist categories prompt selective commercial discounting, moderating quarterly profit growth to low single digits. | $1,182 | $1,657 | $872 | |
| $1,447 | +0.52% | +12.72% | +13.93% | Manufacturing efficiencies across automated production campuses widen gross margins, absorbing domestic price erosion and generating solid sequential cash earnings. | $1,206 | $1,691 | $886 | |
| $1,481 | +2.33% | +15.37% | +16.71% | Sustained free cash flow generation enables accelerated debt retirement and share repurchases, reinforcing per-share intrinsic value despite broader macro deceleration. | $1,242 | $1,741 | $910 | |
| $1,503 | +1.52% | +17.09% | +18.55% | Publication of statutory Medicare Maximum Fair Price schedules enforces structural price adjustments, curbing multiple expansion while baseline volumes remain resilient. | $1,229 | $1,776 | $916 | |
| $1,531 | +1.84% | +19.27% | +20.87% | International sales expansion across Asia and Latin America compensates for domestic pricing friction, maintaining steady operating cash-flow generation. | $1,254 | $1,794 | $937 | |
| $1,537 | +0.39% | +19.74% | +21.45% | Maturing incretin market penetration shifts institutional focus toward defensive cash harvesting, resulting in modest, earnings-backed quarterly equity appreciation. | $1,267 | $1,830 | $947 | |
| $1,571 | +2.22% | +22.38% | +24.25% | Advancements in next-generation amylin and neurodegenerative pipelines extend the intellectual property runway, supporting terminal valuation multiples into year-end. | $1,292 | $1,866 | $970 | |
| $1,589 | +1.18% | +23.79% | +25.79% | Fiscal 2030 results validate over thirty-five billion dollars in distributable free cash flow, translating business compounding into steady share gains. | $1,266 | $1,885 | $980 | |
| $1,609 | +1.23% | +25.34% | +27.49% | Stable chronic refill demand insulates operations from late-cycle economic headwinds, though early biosimilar preparation headlines restrict multiple re-expansion. | $1,291 | $1,904 | $1,000 | |
| $1,630 | +1.33% | +26.98% | +29.27% | The five-year forecast culminates with the enterprise operating as a mature global cash generator, cementing durable low-double-digit compounding returns. | $1,304 | $1,923 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Eli Lilly and Stock Analysis & Scenarios Deep Dive
Eli Lilly and: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Outside market consensus views the company as an unassailable biopharmaceutical monopoly destined for frictionless thirty-percent annual growth. Investors anchor on boundless global obesity demand, expecting oral therapies to simply stack on top of injectable sales without margin dilution. The prevailing narrative assumes permanent pricing hegemony, blithely discounting sovereign reimbursement pushback and higher interest rates.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd materially overestimates the permanence of peak gross pricing power while underestimating the structural cash conversion of maturing manufacturing assets. External models focus on list prices, ignoring inevitable gross-to-net erosion from statutory Medicare caps and commercial pharmacy benefit manager rebates. However, the market simultaneously overlooks how oral small-molecule synthesis eliminates cold-chain capital intensity, unlocking massive low-cost volume that generates superior free cash conversion.
Repricing Catalyst
What could make the market recognize and close that gap? Transparent net price disclosures in upcoming audited filings, coupled with initial commercial prescription data for oral orforglipron through 2027, will force a market repricing. Investors will directly observe that revenue growth is powered by explosive unit volume rather than pricing power, compelling an orderly valuation multiple compression alongside significant upward revisions in cash generation.
Eli Lilly and: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Greed
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Momentum
Most perspectives observe strong momentum driven by commercial adoption, yet disagree sharply on cycle maturity. Optimists view expansion as early-stage, whereas contrarians warn of an overshoot vulnerable to rapid multiple contraction as statutory price negotiations commence.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of restrictive monetary policy and ten-year Treasury yields hovering near five percent is a clear valuation headwind for high-multiple equities. However, cardiometabolic disease treatments exhibit virtually zero economic cyclicality; highly inelastic patient demand completely insulates core operating cash flows from broader stagflationary pressures.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical debate centers on valuation sensitivity and the trajectory of net price realization. Bullish perspectives argue that manufacturing debottlenecking, primary-care oral distribution, and label expansions into sleep apnea and heart failure will drive earnings growth that easily defends premium valuation multiples. Conversely, contrarians demonstrate that statutory Medicare price negotiations and commercial pharmacy benefit manager rebates will compress realized prices by low-to-mid-teens percentages annually. This disagreement will be resolved as quarterly SEC disclosures reveal whether gross margins can hold above eighty-two percent as volume expands.
Eli Lilly and: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Incretin franchise volume scaling | Competitive Positioning | +30% | +50% | Tirzepatide maintains undisputed clinical efficacy, converting diabetes and obesity treatment into chronic maintenance therapy. Expanding manufacturing capacity unlocks global commercial delivery, driving prescription volumes that easily overwhelm low-to-mid-teens gross-to-net realized price concessions and generating massive operational leverage. |
| Oral small molecule primary care expansion | Innovation And Product | +24% | +35% | Commercial rollout of oral orforglipron bypasses cold-chain logistics and autoinjector shortages, opening primary-care and emerging-market channels. Low chemical synthesis costs elevate gross margins, accelerating cash conversion and dramatically broadening the treated patient pool beyond injectable cohorts. |
| Triple agonist clinical differentiation | Innovation And Product | +20% | +28% | Pivotal Phase 3 data for retatrutide demonstrating unprecedented weight reduction establishes an insurmountable clinical moat in severe metabolic disease. This clinical superiority protects premium formulary placement and insulates future corporate revenues against early-generation peptide generic erosion. |
| Manufacturing scale drives operating leverage | Operational Efficiency | +16% | +22% | Multi-billion-dollar domestic and international capital deployments are transitioning from cash-absorptive construction into operational production. Yield optimization and fixed-cost dilution reduce unit production costs, expanding operating margins toward forty-six percent and generating prolific free cash flow. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation multiple contraction under rate gravity | Macroeconomic And Macrofinancial | -18% | -3.0% | Persistent benchmark Treasury yields near five percent and restrictive monetary policy elevate equity discount rates. A trailing price-to-earnings multiple of nearly thirty-nine times faces mechanical compression toward historical pharmaceutical averages of twenty-two to twenty-six times, dampening equity returns. |
| Statutory drug price negotiations and discounts | Regulatory | -16% | -20% | Implementation of Inflation Reduction Act mechanisms and mandatory statutory caps forces significant gross-to-net price concessions across government and commercial programs. This institutional price erosion constrains unit profitability, requiring relentless volume expansion merely to preserve margin health. |
| Competitive pipeline crowding and rebate warfare | Competitive Positioning | -12% | -15% | Rival combination therapies, next-generation oral incretins, and compounded peptide alternatives enter commercial channels. Pharmacy benefit managers leverage competing options to demand steeper formulary rebates, eroding pricing leverage and forcing defensive commercial marketing expenditures. |
| Heavy pipeline development and fixed depreciation | Capital Allocation | -9.0% | -11% | Capitalizing newly commissioned manufacturing facilities introduces substantial depreciation charges onto the income statement. Concurrently, recurring multi-billion-dollar acquired research and development outlays compete with shareholder distributions, keeping distributable cash flow below headline net income. |
Eli Lilly and: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 47/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Severe idiosyncratic class wide safety restriction | 16% | -34% | Emergence of a verified, severe adverse post-marketing safety signal—such as persistent gastrointestinal dysmotility or oncogenic pathology—could prompt FDA black-box warnings. Such intervention would trigger sudden patient discontinuations, severe product liability litigation, and a catastrophic derating of the core metabolic franchise valuation. |
| Radical mandatory statutory price parity decrees | 22% | -28% | Aggressive executive decrees or statutory cost-containment reforms tying domestic metabolic reimbursement directly to international reference prices would dismantle US commercial pricing structures. Slashing net realized prices by fifty percent would destroy operating leverage, gutting free cash generation and wiping out hundreds of billions in market capitalization. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Universal statutory obesity coverage mandate | 34% | +28% | Bipartisan passage of federal legislation or binding CMS rulemaking mandating universal Medicare and commercial coverage for anti-obesity medications would instantly unlock forty million insured lives. This policy breakthrough would overwhelm statutory price discounts, adding over fifteen billion dollars in annual revenue and triggering aggressive multiple expansion. |
| Definitive neurodegenerative disease modification victory | 23% | +22% | Landmark Phase 3 readouts demonstrating profound slowing of cognitive decline for donanemab or next-generation tau conjugates would establish a second multi-billion-dollar therapeutic pillar. Validating disease modification beyond incretins would eliminate single-franchise concentration risk, unlocking substantial institutional scarcity premiums and re-rating the firm's terminal valuation. |
Company Financial AnalysisEli Lilly and: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Eli Lilly and financials here.
Earnings and financials
The latest financial performance illustrates an extraordinary volume-driven expansion. Trailing twelve-month revenue surged to nearly eighty billion dollars, propelled by explosive prescription demand for diabetes and weight-loss blockbusters that overwhelmed single-digit price discounts. Net income expanded dramatically to over twenty-six billion dollars as fixed corporate overhead was spread across massive unit sales. However, headline accounting figures conceal important cash details. While trailing free cash flow reached a record twenty billion dollars, recurring multi-billion-dollar charges for acquired research partnerships continue to absorb cash. The underlying business is growing exceptionally fast, but investors must recognize that ongoing pipeline acquisitions remain an essential expense to maintain long-term leadership.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 65.2B | USD 20.6B | USD 9B |
| 2024 | USD 45B | USD 10.6B | USD 414.3M |
| 2023 | USD 34.1B | USD 5.2B | USD -3.2B |
| 2022 | USD 28.5B | USD 6.2B | USD 4.6B |
| 2021 | USD 28.3B | USD 5.6B | USD 5.4B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 46.8x | TTM | Native | USD / USD |
| 2024 | 65.8x | TTM | Native | USD / USD |
| 2023 | >100x | TTM | Native | USD / USD |
| 2022 | 55.7x | Annual | Native | USD / USD |
| 2021 | 47.2x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profitability has expanded to historic highs, with gross profit margins reaching eighty-three percent and operating margins widening to nearly forty-six percent. This remarkable efficiency reflects immense manufacturing scale and a favorable shift toward high-margin metabolic treatments that cost relatively little to produce once factories are running. These elite margins face an inevitable tug-of-war. Growing government price caps and insurance rebates will push realized selling prices lower, but newly approved daily pills have much cheaper production and shipping costs than refrigerated injections. This structural cost advantage should keep long-term operating profit margins exceptionally strong near forty-four percent.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 29.7B | 45.6% | 31.7% |
| 2024 | USD 17B | 37.8% | 23.5% |
| 2023 | USD 10.8B | 31.6% | 15.4% |
| 2022 | USD 8.7B | 30.3% | 21.9% |
| 2021 | USD 7.9B | 28.0% | 19.7% |
Balance sheet and leverage
The company's balance sheet has strengthened dramatically, supported by total assets expanding to one hundred twelve billion dollars and stockholders' equity nearly doubling to over twenty-six billion dollars. Explosive operational earnings have driven interest coverage to an impregnable thirty-seven times, rendering debt obligations exceptionally safe despite high interest rates. headline net debt of roughly forty-six billion dollars reflects aggressive strategic expansion rather than operating distress. Surging annual cash flow easily handles upcoming debt maturities, granting management complete autonomy to fund clinical trials and selective acquisitions without needing to borrow expensive capital or issue dilutive new shares.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 42.5B | USD 7.3B | USD 35.3B net debt | USD 35.2B | 1.58x |
| 2024 | USD 33.6B | USD 3.4B | USD 30.4B net debt | USD 30.2B | 1.15x |
| 2023 | USD 25.2B | USD 2.9B | USD 22.4B net debt | USD 22.3B | 0.94x |
| 2022 | USD 16.2B | USD 2.2B | USD 14.2B net debt | USD 14B | 1.05x |
| 2021 | USD 16.9B | USD 3.9B | USD 13.1B net debt | USD 13B | 1.23x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management has executed a massive, multi-year industrial building campaign, pouring tens of billions of dollars into high-tech manufacturing plants across Indiana, North Carolina, and Europe. Capital expenditure consumed nearly nineteen percent of revenue in 2024 before moderating to twelve percent in 2025 as major facility phases reached completion. This aggressive spending was necessary to eliminate chronic drug shortages and build automated facilities that competitors cannot easily replicate. Because the heaviest construction phase is now cresting, future capital spending will moderate relative to sales. This unlocks billions in surplus cash flow that can be redirected toward shareholder dividends and share buybacks.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 7.8B | USD 13.3B |
| 2024 | USD 8.4B | USD 11B |
| 2023 | USD 7.4B | USD 9.3B |
| 2022 | USD 2.5B | USD 7.2B |
| 2021 | USD 1.9B | USD 6.9B |
Behind the synthesisEli Lilly and: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The independently supported consensus reveals an extraordinary operational transition: massive volume expansion driven by tirzepatide indications, the commercial scaling of oral small-molecule orforglipron, and late-stage retatrutide clinical data. Most submissions agree that multi-billion-dollar domestic biomanufacturing investments have passed peak capital intensity, unlocking substantial free cash flow conversion. However, reports heavily correlated around unconstrained growth overlook critical gross-to-net price erosion and statutory Medicare drug price negotiations. The strongest contrarian case establishes that realized prices face low-to-mid-teens annual deflation and that persistent five percent benchmark bond yields will grind trailing valuation multiples toward historical sector norms. We assign higher weights to forensic analyses that rigorously reconcile cash-flow statements by isolating acquired research charges from core manufacturing capital expenditures. Unresolved uncertainty centers on whether unit volume elasticity can fully outrun sovereign price caps.
All 14 opinions
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 12.5%
Provides exemplary empirical rigor, independently reconciling Form 10-K and 10-Q cash flow discrepancies while distinguishing manufacturing capital expenditures from acquired research charges. Its realistic price-for-access trade-off deserves substantial weight.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 10.4%
Supplies an indispensable contrarian analysis grounded in the CMS BALANCE agreement and mandatory statutory discounts. Its critique of terminal multiple fragility and fixed-plant depreciation provides a crucial risk check against excessive market optimism.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.3%
Provides exceptional institutional insights into regulatory compounding exclusions and pharmacy benefit manager dynamics. Its assessment of small-molecule oral manufacturing advantages is well reasoned, balancing political headline risk against durable volume expansion.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.3%
Delivers balanced macroeconomic debt-cycle integration, correctly identifying interest rate gravity on long-duration equities while detailing volume elasticity across international markets. Its moderate compounding path remains highly credible.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.3%
Performs detailed forensic cash-flow analysis, successfully isolating cresting capital expenditures from recurring acquired research charges. It accurately traces how small-molecule oral economics counteract injectable gross-to-net realized price dilution.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.3%
This report provides rigorous owner-earnings analysis and recognizes post-peak capital intensity. However, its valuation scenario assumes aggressive multiple compression without fully accounting for non-incretin pipeline optionality, warranting a modest weighting within consensus.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.3%
Features solid multi-disciplinary modeling of the transition to oral distribution, balancing cost-of-goods efficiency against statutory Medicare negotiations. Minor overlap with sister reports slightly curbs its standalone marginal weight.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.3%
Demonstrates sound intrinsic value discipline, correctly projecting multiple compression against five percent Treasury yields while tracking owner earnings growth. The path aligns well with prudent capital allocation expectations.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.3%
Offers detailed commercial scaling projections across primary care but incorporates overly aggressive multiple preservation and top-line growth assumptions that understate gross-to-net rebate concessions and sovereign price scrutiny.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.3%
Presents strong structural reasoning regarding supply negentropy and fixed-cost absorption. Nevertheless, its philosophical framing occasionally obscures granular near-term pricing friction and commercial discount mechanics, justifying a standard allocation.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.3%
Constructs a robust operational narrative detailing the progression from injectable capacity constraints to oral and triple-agonist market breadth. However, its equity return assumptions lean slightly higher than macroeconomic discount rates justify.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.2%
Presents innovative biological demand arguments and tracks oral manufacturing advantages, but incorporates somewhat optimistic margin trajectories that understate impending statutory price negotiations and geopolitical tariff frictions.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.2%
Captures first-principles industrial scaling dynamics across advanced manufacturing campuses effectively, though its long-term revenue targets underplay formulary step-therapy hurdles and competitive biosimilar entries.
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 1.0%
Demonstrates strong primary research and patent timeline verification, but its factual baseline relies on post-cutoff future reporting and forward-dated regulatory artifacts, necessitating a minimal weighting for audit compliance.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Eli Lilly and forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web36 available sources from this batch (64 recorded). The first 15 are shown below; expand to read the rest.
- Medicare GLP-1 Bridge | CMS cms.gov
- Document sec.gov
- ELI LILLY & Co - Form 8-K - FY2026 sec.gov
- lly-20251231 sec.gov
- lly-20260630 sec.gov
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress | Eli Lilly and Company investor.lilly.com
- Eli Lilly (LLY) Earnings Report Q2 2026 | Beat, EPS & Revenue | 24/7 Wall St. 247wallst.com
- FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity | AJMC ajmc.com
- Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices | AJMC ajmc.com
- Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s | AMCP.org amcp.org
- Eli Lilly Q2 2026 results: revenue +48%, raises guidance; retatrutide package complete chemxplore.com
- Eli Lilly (LLY) earnings Q2 2026 cnbc.com
- When do the MOUNJARO patents expire, and when will generic MOUNJARO be available? drugpatentwatch.com
- FDA Accepts Sandoz Applications for Generic Tirzepatide | Drug Topics drugtopics.com
- Lilly builds sizable store of orforglipron ahead of FDA verdict fiercepharma.com
Show 21 more sources
- Eli Lilly (LLY) Gets a Big Price Target Boost, Analysts See 20% Upside finance.yahoo.com
- Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead | FirstWord Pharma firstwordpharma.com
- As Most Favored Nation Drug Price Deals Stay Secret, Burning Questions Remain forbes.com
- When Will Zepbound Be Cheaper? The Patent Timeline, Biosimilar Entry, and What You Can Do Now formblends.com
- Mounjaro patent expiration: Drug patents expiring in 2036 - GreyB greyb.com
- Eli Lilly Q2 2026 Earnings Preview: LLY Revenue, EPS Preview | Hudson Labs hudson-labs.com
- FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions | Eli Lilly and Company investor.lilly.com
- Lilly reports second-quarter 2026 financial results, raises ... investor.lilly.com
- Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health | Eli Lilly and Company investor.lilly.com
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C | Eli Lilly and Company investor.lilly.com
- NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company investor.lilly.com
- Why is Eli Lilly Betting Big on Orforglipron with a $1.5 Billion Inventory kavout.com
- Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility | Eli Lilly and Company lilly.gcs-web.com
- News Details novonordisk.com
- News Details novonordisk.com
- Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy | Pharmacy Times pharmacytimes.com
- Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade | PharmExec pharmexec.com
- Eli Lilly (NYSE:LLY) - Stock Analysis - Simply Wall St simplywall.st
- Eli Lilly and Company (LLY) Stock Forecast & Price Targets stockanalysis.com
- Eli Lilly and Company (LLY) Stock Price & Overview stockanalysis.com
- TrimRX | When Will Tirzepatide Go Generic? Patent Timeline & Biosimilar Outlook trimrx.com
28 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.